Clinical Research Center, The Seventh Affiliated Hospital, Sun Yat-Sen University, Shenzhen, Guangdong, China.
Big Data Center, Scientific Research Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong, China.
Gut. 2021 Jun;70(6):1070-1077. doi: 10.1136/gutjnl-2020-322557. Epub 2020 Sep 28.
The association between the regular use of proton pump inhibitors (PPIs) and the risk of type 2 diabetes remains unclear, although a recent randomised controlled trial showed a trend towards increased risk. This study was undertaken to evaluate the regular use of PPIs and risk of type 2 diabetes.
This is a prospective analysis of 204 689 participants free of diabetes in the Nurses' Health Study (NHS), NHS II and Health Professionals Follow-up Study (HPFS). Type 2 diabetes was confirmed using American Diabetes Association (ADA) diagnostic criteria. We evaluated hazard ratios (HRs) adjusting for demographic factors, lifestyle habits, the presence of comorbidities, use of other medications and clinical indications.
We documented 10 105 incident cases of diabetes over 2 127 471 person-years of follow-up. Regular PPI users had a 24% higher risk of diabetes than non-users (HR 1.24, 95% CI 1.17 to 1.31). The risk of diabetes increased with duration of PPI use. Fully adjusted HRs were 1.05 (95% CI 0.93 to 1.19) for participants who used PPIs for >0-2 years and 1.26 (95% CI 1.18 to 1.35) for participants who used PPIs for >2 years compared with non-users.
Regular use of PPIs was associated with a higher risk of type 2 diabetes and the risk increased with longer duration of use. Physicians should therefore exercise caution when prescribing PPIs, particularly for long-term use.
质子泵抑制剂(PPIs)的常规使用与 2 型糖尿病风险之间的关联尚不清楚,尽管最近的一项随机对照试验显示风险有增加的趋势。本研究旨在评估 PPI 的常规使用与 2 型糖尿病风险之间的关系。
这是对护士健康研究(NHS)、NHS II 和健康专业人员随访研究(HPFS)中 204689 例无糖尿病参与者的前瞻性分析。使用美国糖尿病协会(ADA)诊断标准确诊 2 型糖尿病。我们通过调整人口统计学因素、生活方式习惯、合并症的存在、其他药物的使用和临床指征来评估危害比(HRs)。
我们在 2127471 人年的随访中记录了 10105 例糖尿病新发病例。与非使用者相比,常规使用 PPI 的患者发生糖尿病的风险增加了 24%(HR 1.24,95%CI 1.17-1.31)。使用 PPI 的时间与糖尿病风险之间存在相关性。完全调整后的 HRs 分别为:使用 PPI >0-2 年的参与者为 1.05(95%CI 0.93-1.19),使用 PPI >2 年的参与者为 1.26(95%CI 1.18-1.35),与非使用者相比。
常规使用 PPI 与 2 型糖尿病风险增加相关,且风险随使用时间的延长而增加。因此,医生在开具 PPI 处方时应谨慎,特别是对于长期使用。